Shen Yulei, Zheng Yumin, Liu Zhening, Liang Rui, Yan Yue, Long Hongzhu, Liu Shixuan, Cui Huijuan
Department of Graduate School, Beijing University of Chinese Medicine, Beijing 100105, P.R. China.
Department of Traditional and Western Medicine for Pulmonary Diseases, China-Japan Friendship Hospital, Beijing 100029, P.R. China.
Oncol Lett. 2024 Nov 27;29(2):80. doi: 10.3892/ol.2024.14826. eCollection 2025 Feb.
Tumor metastasis is a phenomenon in which tumor cells grow in distant organs far from their primary site and is the final and most lethal manifestation of cancer. Most patients with cancer succumb to metastatic disease, not primary tumors. The occurrence of cardiac metastases is rare, but any primary tumor can potentially metastasize to the heart. The present report describes a 71-year-old male with stage IV lung squamous cell carcinoma who was diagnosed with cardiac metastases. These were identified as pedicled structures in the left atrium and left ventricle via echocardiography and positron emission tomography/computed tomography (PET/CT) prior to curative therapy. PET/CT imaging confirmed increased uptake of the tracer in these regions, indicating malignancy. Given the high expression of programmed cell death-ligand 1, the patient was treated with sintilimab immunotherapy. Despite a transient increase in liver function markers during treatment, the patient completed eight cycles of immunotherapy. Notably, both the primary lung tumor and cardiac metastases were markedly reduced in size, indicating a positive therapeutic response. The present case underscores the potential efficacy of immunotherapy in the management of cardiac metastases originating from lung cancer.
肿瘤转移是一种肿瘤细胞在远离其原发部位的远处器官生长的现象，是癌症最终且最致命的表现形式。大多数癌症患者死于转移性疾病，而非原发性肿瘤。心脏转移的发生较为罕见，但任何原发性肿瘤都有可能转移至心脏。本报告描述了一名71岁的男性IV期肺鳞状细胞癌患者，其被诊断为心脏转移。在进行根治性治疗前，通过超声心动图和正电子发射断层扫描/计算机断层扫描（PET/CT）检查发现这些转移灶为左心房和左心室内的带蒂结构。PET/CT成像证实这些区域示踪剂摄取增加，提示为恶性病变。鉴于程序性细胞死亡配体1的高表达，该患者接受了信迪利单抗免疫治疗。尽管治疗期间肝功能指标出现短暂升高，但患者完成了八个周期的免疫治疗。值得注意的是，原发性肺肿瘤和心脏转移灶的大小均显著缩小，表明治疗反应良好。本病例强调了免疫治疗在管理源自肺癌的心脏转移方面的潜在疗效。
